Skeletal Dysplasia Drugs Global Market Report 2025
상품코드:1769750
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 골격이형성증 치료제 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년까지 CAGR 5.4%, 40억 9,000만 달러로 성장할 것으로 예상됩니다. 이 성장의 원동력은 희귀질환 연구에 대한 투자 증가, 특정 병태를 목표로 하는 치료에 대한 수요 증가, 맞춤형 치료 옵션의 광범위한 가용성, 소아골 질환에 대한 중점 증가, 생명 공학 기업 간의 협력 관계 확대 등입니다. 예측되는 주요 동향은 유전자 편집 기술의 진보, 효소 보충 요법을 제공하는 혁신적인 접근법, 골 재생법의 진보, 희귀 골격 질환에 대한 연구 노력의 강화, 개인화 치료를 위한 플랫폼의 개선 등이 있습니다.
골질환의 유병률 증가는 향후 수년간 골격이형성증 치료제 시장의 성장을 가속할 것으로 예측됩니다. 뼈 장애는 뼈의 강도, 구조, 기능에 영향을 미치는 병리학을 포함하며, 뼈의 약화, 변형, 통증, 골절, 이동성 제한 등의 문제로 이어집니다. 이 증가는 운동 부족이 뼈의 강도와 밀도를 낮추고 골절과 퇴행성 질환의 위험을 증가시키는 앉기 쉬운 라이프 스타일에 크게 기여합니다. 골격이형성증 치료제는 뼈의 성장과 발달에 영향을 미치는 유전적 또는 분자적 원인을 표적으로 함으로써 뼈 장애를 해결하고, 뼈 형성, 강도, 구조를 강화하고, 변형, 골절, 운동 능력 저하 등의 증상을 완화합니다. 예를 들어, 2023년 2월 국립의학 도서관에 따르면 미국에서 인공 고관절 전치환술(THA)과 인공 슬관절 전치환술(TKA) 수술 건수는 2040년까지 각각 71만 9,364건과 122만 2,988건 증가할 것으로 예측되고 있습니다. 게다가 2060년까지 TKA는 291만 7,959건, THA는 198만 2,099건에 이를 것으로 예측되고 있습니다. 이러한 뼈 질환의 유병률 증가는 골격이형성증 치료제 시장을 추진하는 중요한 요인입니다.
골격이형성증 치료제 시장의 주요 기업은 비정상적인 뼈 성장을 일으키는 특정 분자 경로를 조절하는 표적 생물학적 요법과 같은 혁신적인 치료에 주력하고 있습니다. 표적 생물학적 요법은 단백질, 항체, 펩티드 등의 생물학적 약제를 이용하여 질병 과정에 관여하는 분자 표적과 정확하게 상호작용하며, 기존 치료법보다 높은 정밀도와 적은 부 이를 통해 비정상적인 생물학적 기능을 수정하거나 억제하는 것을 목표로 합니다. 적인 예후를 개선하는 2023년 10월, BioMarin Pharmaceutical Inc.는 정상적인 뼈 성장을 촉진하고 장기적인 예후를 계선하는 VOXZOGO(보솔리티드)를 발매했습니다. 이 치료법은 연골 무형성증의 아이들에게, 뼈의 성장을 가속하고, 키를 키우고, 합병증을 줄이고, 전체적인 생활의 질을 높이는 표적 치료를 제공합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 골격이형성증 치료제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 골격이형성증 치료제 시장 : 성장률 분석
세계의 골격이형성증 치료제 시장 실적 : 규모와 성장, 2019-2024년
세계의 골격이형성증 치료제 시장 예측 : 규모와 성장, 2024-2029년, 2034F
세계의 골격이형성증 치료제 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 골격이형성증 치료제 시장 : 치료별 분석과 예측, 2019-2024년, 2024-2029F, 2034F
효소 보충 요법
인간 단일클론항체
기타 치료
세계의 골격이형성증 치료제 시장 : 이형성 유형별 분석과 예측, 2019-2024년, 2024-2029F, 2034F
모르키오 A 증후군
X 연쇄성 저인혈증
저포스파타제증
연골무형성증
진행성 섬유성 골이형성증
다발성 골연골종
기타 이형성 유형
세계의 골격이형성증 치료제 시장 : 유통 채널별 분석과 예측, 2019-2024년, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
세계의 골격이형성증 치료제 시장 : 효소 보충 요법(ERT) 유형별 세분화: 분석과 예측, 2019-2024년, 2024-2029F, 2034F
알글루코시다제 알파
이듀르술파아제
라로니다제
엘리글루스타트
기타 효소 보충 요법(ERT) 약물
세계의 골격이형성증 치료제 시장 : 인간 단일클론항체 유형별 세분화: 분석과 예측, 2019-2024년, 2024-2029F, 2034F
항 FGF 수용체 항체
항 TNF-α 항체
항 IL-6 수용체 항체
기타 인간 단일클론항체
세계의 골격이형성증 치료제 시장 : 기타 치료 유형별 세분화: 분석과 예측, 2019-2024년, 2024-2029F, 2034F
소분자 요법
유전자 치료
RNA 기반 치료
대증요법
지지요법
제7장 지역별/국가별 분석
세계의 골격이형성증 치료제 시장 : 지역별 분석과 예측, 2019-2024년, 2024-2029F, 2034F
세계의 골격이형성증 치료제 시장 : 국가별 분석과 예측, 2019-2024년, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
골격이형성증 치료제 시장 : 경쟁 구도
골격이형성증 치료제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck KGaA : 개요, 제품 및 서비스, 전략 및 재무 분석
Amgen Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Regeneron Pharmaceuticals Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Mayo Clinic : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
The Johns Hopkins Hospital
BridgeBio Pharma Inc.
UCLA Health
Kyowa Kirin Co. Ltd.
BioMarin Pharmaceutical Inc.
ARUP Laboratories
Alexion Pharmaceuticals Inc.
Invitae Corporation
BridgeBio Pharma Inc.
Tyra Biosciences Inc.
Ascendis Pharma A/S
Blueprint Genetics Oy
Clementia Pharmaceuticals Inc.
QED Therapeutics Inc.
InnoSkel SAS
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
골격이형성증 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
골격이형성증 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
골격이형성증 치료제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
JHS
영문 목차
영문목차
Skeletal dysplasia drugs are pharmaceutical treatments designed to manage or modify the genetic and biochemical pathways responsible for abnormal bone and cartilage development in skeletal dysplasia disorders. These drugs aim to promote better bone growth, minimize complications, and improve the quality of life for individuals affected by various skeletal dysplasia conditions.
The primary treatment categories within skeletal dysplasia drugs include enzyme replacement therapy, human monoclonal antibodies, and other therapeutic approaches. Enzyme replacement therapy (ERT) involves supplying the body with synthetic or natural enzymes that are missing or deficient to help restore normal biological function. These treatments target various dysplasia types such as Morquio A syndrome, X-linked hypophosphatemia, hypophosphatasia, achondroplasia, fibrodysplasia ossificans progressiva, multiple osteochondromas, among others, and are made available through different distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies.
The skeletal dysplasia drugs market research report is one of a series of new reports from The Business Research Company that provides skeletal dysplasia drugs market statistics, including skeletal dysplasia drugs industry global market size, regional shares, competitors with skeletal dysplasia drugs market share, skeletal dysplasia drugs market segments, market trends and opportunities, and any further data you may need to thrive in the skeletal dysplasia drugs industry. This skeletal dysplasia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The skeletal dysplasia drugs market size has grown strongly in recent years. It will grow from $3.13 billion in 2024 to $3.31 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The increase seen during the past period is mainly driven by greater awareness of rare bone disorders, a rising number of skeletal dysplasia cases, higher adoption rates of enzyme replacement therapies, expanded access to genetic testing, and improved early diagnosis.
The skeletal dysplasia drugs market size is expected to see strong growth in the next few years. It will grow to $4.09 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. This growth is fueled by increasing investments directed at rare disease research, heightened demand for therapies that target specific conditions, broader availability of customized treatment options, a growing emphasis on pediatric bone disorders, and expanding collaborations among biotechnology companies. Key trends predicted include advancements in gene editing technologies, innovative approaches to delivering enzyme replacement therapies, progress in bone regeneration methods, intensified research efforts into rare skeletal conditions, and improvements in platforms for personalized therapies.
The rising prevalence of bone disorders is expected to drive the growth of the skeletal dysplasia drugs market in the coming years. Bone disorders encompass medical conditions that impact the strength, structure, or function of bones, leading to issues such as weakened bones, deformities, pain, fractures, or limited mobility. This increase is largely attributed to sedentary lifestyles, where insufficient physical activity reduces bone strength and density, heightening the risk of fractures and degenerative conditions. Skeletal dysplasia drugs address bone disorders by targeting the genetic or molecular causes that influence bone growth and development, enhancing bone formation, strength, and structure, and thereby alleviating symptoms like deformities, fractures, and impaired mobility. For example, according to the National Library of Medicine in February 2023, total hip arthroplasty (THA) and total knee arthroplasty (TKA) procedures in the US are projected to rise by 719,364 and 1,222,988 respectively by 2040. Furthermore, by 2060, TKAs are expected to reach 2,917,959, and THAs 1,982,099. This growing prevalence of bone disorders is a key factor propelling the skeletal dysplasia drugs market.
Leading companies in the skeletal dysplasia drugs market are focusing on innovative treatments, such as targeted biological therapies that modulate specific molecular pathways responsible for abnormal bone growth. These therapies enable more effective and safer treatment options tailored to the genetic defects underlying the conditions. Targeted biological therapies utilize biologically derived agents like proteins, antibodies, or peptides to precisely interact with molecular targets involved in the disease process, aiming to correct or inhibit abnormal biological functions with greater accuracy and fewer side effects than traditional treatments. For instance, in October 2023, BioMarin Pharmaceutical Inc., a biotechnology firm based in the US, launched VOXZOGO (vosoritide) to promote normal bone growth and improve long-term outcomes. This therapy offers children with achondroplasia a targeted treatment that encourages bone growth, increases height, reduces complications, and enhances overall quality of life.
In February 2024, Bridge Bio Pharma Inc., a US-based biotechnology company, partnered with Kyowa Kirin to advance the development and availability of infigratinib for treating skeletal dysplasias in Japan, addressing a significant unmet medical need. Kyowa Kirin Co. Ltd., a pharmaceutical and biotechnology company headquartered in Japan, is actively involved in the skeletal dysplasia drugs sector.
Major players in the skeletal dysplasia drugs market are Pfizer Inc., Merck KGaA, Amgen Inc., Regeneron Pharmaceuticals Inc., Mayo Clinic, The Johns Hopkins Hospital, BridgeBio Pharma Inc., UCLA Health, Kyowa Kirin Co. Ltd., BioMarin Pharmaceutical Inc., ARUP Laboratories, Alexion Pharmaceuticals Inc., Invitae Corporation, BridgeBio Pharma Inc., Tyra Biosciences Inc., Ascendis Pharma A/S, Blueprint Genetics Oy, Clementia Pharmaceuticals Inc., QED Therapeutics Inc., InnoSkel SAS.
North America was the largest region in the skeletal dysplasia drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in skeletal dysplasia drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the skeletal dysplasia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The skeletal dysplasia drugs market consists of sales of C-type natriuretic peptide (CNP) analogs, enzyme replacement therapies, anti-inflammatory drugs, fibroblast growth factor receptor (FGFR) inhibitors and gene therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in usd, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Skeletal Dysplasia Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on skeletal dysplasia drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for skeletal dysplasia drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The skeletal dysplasia drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment: Enzyme Replacement Therapy; Human Monoclonal Antibody; Other Treatments
2) By Dysplasia Type: Morquio A Syndrome; X-Linked Hypophosphatemia; Hypophosphatasia; Achondroplasia; Fibrodysplasia Ossificans Progressive; Multiple Osteochondromas; Other Dysplasia Types
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Enzyme Replacement Therapy (ERT): Alglucosidase Alfa; Idursulfase; Laronidase; Eliglustat; Other Enzyme Replacement Therapy (ERT) Drug
2) By Human Monoclonal Antibody: Anti-FGF Receptor Antibodies; Anti-TNF-Alpha Antibodies; Anti-IL-6 Receptor Antibodies; Other Human Monoclonal Antibody
3) By Other Treatments: Small Molecule Therapies; Gene Therapy; RNA-Based Therapies; Symptomatic Treatments; Supportive Therapies
3. Skeletal Dysplasia Drugs Market Trends And Strategies
4. Skeletal Dysplasia Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Skeletal Dysplasia Drugs Growth Analysis And Strategic Analysis Framework
5.1. Global Skeletal Dysplasia Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Skeletal Dysplasia Drugs Market Growth Rate Analysis
5.4. Global Skeletal Dysplasia Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Skeletal Dysplasia Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Skeletal Dysplasia Drugs Total Addressable Market (TAM)
6. Skeletal Dysplasia Drugs Market Segmentation
6.1. Global Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enzyme Replacement Therapy
Human Monoclonal Antibody
Other Treatments
6.2. Global Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Morquio A Syndrome
X-Linked Hypophosphatemia
Hypophosphatasia
Achondroplasia
Fibrodysplasia Ossificans Progressive
Multiple Osteochondromas
Other Dysplasia Types
6.3. Global Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Skeletal Dysplasia Drugs Market, Sub-Segmentation Of Enzyme Replacement Therapy (ERT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Alglucosidase Alfa
Idursulfase
Laronidase
Eliglustat
Other Enzyme Replacement Therapy (ERT) drugs
6.5. Global Skeletal Dysplasia Drugs Market, Sub-Segmentation Of Human Monoclonal Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anti-FGF Receptor Antibodies
Anti-TNF-Alpha Antibodies
Anti-IL-6 Receptor Antibodies
Other Human Monoclonal Antibody
6.6. Global Skeletal Dysplasia Drugs Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Molecule Therapies
Gene Therapy
RNA-Based Therapies
Symptomatic Treatments
Supportive Therapies
7. Skeletal Dysplasia Drugs Market Regional And Country Analysis
7.1. Global Skeletal Dysplasia Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Skeletal Dysplasia Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Skeletal Dysplasia Drugs Market
9.1. China Skeletal Dysplasia Drugs Market Overview
9.2. China Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Skeletal Dysplasia Drugs Market
10.1. India Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Skeletal Dysplasia Drugs Market
11.1. Japan Skeletal Dysplasia Drugs Market Overview
11.2. Japan Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Skeletal Dysplasia Drugs Market
12.1. Australia Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Skeletal Dysplasia Drugs Market
13.1. Indonesia Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Skeletal Dysplasia Drugs Market
14.1. South Korea Skeletal Dysplasia Drugs Market Overview
14.2. South Korea Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Skeletal Dysplasia Drugs Market
15.1. Western Europe Skeletal Dysplasia Drugs Market Overview
15.2. Western Europe Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Skeletal Dysplasia Drugs Market
16.1. UK Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Skeletal Dysplasia Drugs Market
17.1. Germany Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Skeletal Dysplasia Drugs Market
18.1. France Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Skeletal Dysplasia Drugs Market
19.1. Italy Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Skeletal Dysplasia Drugs Market
20.1. Spain Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Skeletal Dysplasia Drugs Market
21.1. Eastern Europe Skeletal Dysplasia Drugs Market Overview
21.2. Eastern Europe Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Skeletal Dysplasia Drugs Market
22.1. Russia Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Skeletal Dysplasia Drugs Market
23.1. North America Skeletal Dysplasia Drugs Market Overview
23.2. North America Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Skeletal Dysplasia Drugs Market
24.1. USA Skeletal Dysplasia Drugs Market Overview
24.2. USA Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Skeletal Dysplasia Drugs Market
26.1. South America Skeletal Dysplasia Drugs Market Overview
26.2. South America Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Skeletal Dysplasia Drugs Market
27.1. Brazil Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Skeletal Dysplasia Drugs Market
28.1. Middle East Skeletal Dysplasia Drugs Market Overview
28.2. Middle East Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Skeletal Dysplasia Drugs Market
29.1. Africa Skeletal Dysplasia Drugs Market Overview
29.2. Africa Skeletal Dysplasia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Skeletal Dysplasia Drugs Market, Segmentation By Dysplasia Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Skeletal Dysplasia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Skeletal Dysplasia Drugs Market Competitive Landscape And Company Profiles
